New Tool Maps Cancer Cell’s Genetic Rewriting for Potential Therapies

Researchers have developed a new method for measuring how cancer cells alter their genetic instructions – a process known as splicing – to promote growth and survival. The technique, detailed in a recent Nature Communications study, offers a clearer view of a tumor’s internal workings and has already identified around 120 potential targets for new cancer therapies. This isn’t about identifying faulty genes themselves, but understanding how cells creatively rearrange the instructions within those genes to fuel the disease.

For years, scientists have known that cancer cells hijack the natural process of splicing, where segments of genetic messages are cut out and others stitched together before a gene’s instructions are used to create proteins. This editing allows a single gene to produce a variety of proteins, essential for normal cellular function. But in cancer, this process is corrupted, leading to the production of proteins that accelerate growth, help tumors evade the immune system, or resist treatment. The challenge has been understanding how this editing happens systematically, and what drives it.

Measuring the Outcome, Not Just the Editors

Traditionally, researchers have focused on measuring the molecules responsible for splicing – the “splicing factors.” However, these factors are subject to complex regulation, meaning their levels don’t always accurately reflect the actual editing taking place. A splicing factor might appear abundant, but the protein itself could be degraded, chemically modified, or relocated within the cell, masking its true activity. This creates a confusing picture and hinders the search for effective therapies.

The team at the Center for Genomic Regulation in Barcelona and Columbia University took a different approach. They focused on measuring the results of splicing – which segments of a gene’s message are kept and which are removed – rather than the activity of the splicing factors themselves. This shift in perspective, as described by Dr. Miquel Anglada Girotto, the study’s first author, allows researchers to “understand behavior” and unlock a new way to navigate the complex biology of tumors. “It’s early, but it gives us a much clearer map of where to look for to find new ways of targeting the disease,” he stated.

To achieve this, the researchers adapted a technology called VIPER (Versatile In-situ Partitioning and Editing Reporter) to measure these splicing patterns. These patterns act like fingerprints, revealing which editing forces are at play, regardless of how the splicing factors are regulated. Importantly, the technique can be applied to existing RNA sequencing data, meaning it can be used to analyze thousands of samples without requiring new experiments. This existing database offers a significant advantage for accelerating research.

Two Common Editing Programs in Cancer

The researchers applied VIPER to approximately 10,000 tumor biopsies from 14 different cancer types within The Cancer Genome Atlas, a publicly available database. By comparing each biopsy to matched healthy tissue samples, they identified two broad cellular editing programs that repeatedly appeared across all cancer types. One program acted as an “accelerator,” becoming more active in tumors and correlating with poorer patient outcomes. The other functioned as a “brake,” losing strength in cancer and associating with better survival rates.

This discovery suggests that despite the diversity of cancers, they share common strategies for altering their genetic instructions. It highlights a previously hidden layer of complexity in cancer biology, one that goes beyond simply identifying mutated genes. The findings suggest that cancers, despite their varied origins, converge on similar editing strategies.

Further analysis revealed around 100 candidate genes that influence the balance of these editing programs. Among them, the gene FUS stood out. While better known for its role in neurological conditions, its strong predictive signal suggests it may play a more significant role in cancer than previously appreciated. Recent research has focused on identifying driver genes in cancer, and FUS may be a key player.

Beyond Cancer: A Versatile Technique

The implications of this research extend beyond cancer. Since the VIPER technique focuses on the outcome of genetic editing, rather than the specific cause, it could be applied to a wide range of diseases where cells alter how they assemble their genetic messages. Dr. Anglada Girotto notes that the approach could be valuable in studying neurological disorders and immune diseases, among others.

This new tool provides a more nuanced understanding of how cancer cells function, moving beyond a simple focus on gene mutations to examine the dynamic process of genetic editing. While still in its early stages, this research offers a promising new avenue for developing more targeted and effective cancer therapies. The ability to analyze existing datasets using VIPER means this approach could rapidly accelerate the identification of new therapeutic targets and improve our understanding of cancer’s complex biology.

Nature Communications (2026). DOI: 10.1038/s41467-026-69642-3

Journal information: Nature Communications

Provided by Center for Genomic Regulation